Informace o publikaci
Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry
| Autoři | |
|---|---|
| Rok publikování | 2021 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | WORLD ALLERGY ORGANIZATION JOURNAL |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://www.worldallergyorganizationjournal.org/article/S1939-4551(21)00029-6/pdf |
| Doi | http://dx.doi.org/10.1016/j.waojou.2021.100535 |
| Klíčová slova | Angioedema; Hereditary; Complement C1 inhibitor protein; Recombinant human C1 esterase inhibitor; Registry; Ruconest |
| Popis | Background: Hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (C1-INHHAE) is characterized by recurrent swelling attacks. A European treatment registry was established to review the adverse event profile and efficacy of recombinant human C1 esterase inhibitor (rhC1-INH) for HAE attacks. Methods: Individuals with C1-INH-HAE were enrolled following a decision to treat with rhC1-INH and provision of written informed consent. Medical history and baseline HAE information were collected at screening. Healthcare providers entered data on HAE attacks, response to treatment, and adverse events using a web-based questionnaire. Results: From July 1, 2011, through December 1, 2019, 71 patients with C1-INH-HAE (30 male/ 41 female; mean age, 47.3 years; age range, 19 & ndash;78 years) in 9 countries reported 2356 attacks and were treated with rhC1-INH. Before registry entry, patients, including 20 (28.2%) who were on maintenance therapy/prophylaxis at registry enrollment, experienced a mean of 25 HAE attacks per year (median, 16 [range, 0 & ndash;185]). Most treated HAE attacks were abdominal (46.1%), followed by peripheral (38.3%), oro-facial-pharyngeal (14.8%), urogenital (3.2%), and laryngeal (2.6%). The mean rhC1-INH dose was 3307 U (43.3 U/kg). Patients reported symptom improvement within 4 h for 97.8% of attacks (2305/2356) with rhC1-INH; most attacks (99.8%; 2351/2356) required only 1 dose. Five attacks were treated with a second dose (total rhC1-INH dose administered for attack, 4200 U). No hypersensitivity, thrombotic/thromboembolic events, or drug-related serious adverse events were reported. Conclusion: The rhC1-INH treatment registry provided real-world data on the treatment of 2356 HAE attacks that were consistent with clinical trial data of rhC1-INH in patients with C1-INH-HAE. |